Publikationen, an denen er mitarbeitet José Luis Lanciego Pérez (29)

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  4. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

2021

  1. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

2018

  1. Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

    Neurotherapeutics, Vol. 15, Núm. 4, pp. 1063-1081

  2. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  3. Glucocerebrosidase expression patterns in the non-human primate brain

    Brain Structure and Function, Vol. 223, Núm. 1, pp. 343-355

  4. Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans

    Molecular Neurobiology, Vol. 55, Núm. 7, pp. 5847-5867

  5. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia

    Brain, Behavior, and Immunity, Vol. 67, pp. 139-151

  6. Usefulness of identifying g-protein-coupled receptor dimers for diagnosis and therapy of neurodegenerative diseases and of gliomas

    Histology and Histopathology, Vol. 33, Núm. 9, pp. 909-917

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

  2. Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells

    Brain Structure and Function, Vol. 222, Núm. 6, pp. 2559-2571

  3. Neurochemical evidence supporting dopamine D1–D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation

    Brain Structure and Function, Vol. 222, Núm. 4, pp. 1767-1784

2016

  1. Hints on the Lateralization of Dopamine Binding to D 1 Receptors in Rat Striatum

    Molecular Neurobiology, Vol. 53, Núm. 8, pp. 5436-5445

  2. Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration

    Cell Death and Disease, Vol. 7, Núm. 10

2015

  1. Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats

    Neurobiology of Aging, Vol. 36, Núm. 2, pp. 1194-1208

  2. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism

    Brain Structure and Function, Vol. 220, Núm. 5, pp. 2721-2738

  3. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum

    Biochemical Pharmacology, Vol. 96, Núm. 2, pp. 131-142

  4. Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia

    Molecular Neurobiology, Vol. 52, Núm. 3, pp. 1408-1420